Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with SOX for stage IV gastric cancer
ChiCTR1900026291Phase 4Not yet recruiting
- Sponsor
- Gangji Medical
- Start
- Oct 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib, tegafur and oxaliplatin in gastric cancer (GC), sponsored by Gangji Medical. Primary endpoints: objective response rate, progression-free survival and 2 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
anlotinibtegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1900026291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026291.